Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760575 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
A Phase 1 study of Mesotheliomas Pleural, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03760575: Recruiting Phase 1 study of Mesotheliomas Pleural, sponsored by Abramson Cancer Center at Penn Medicine.
NCT03760575 is a Phase 1 study of Mesotheliomas Pleural that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 20 participants, below the 32-participant average among 4 other Mesotheliomas Pleural trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03760575, a Phase 1 study of Mesotheliomas Pleural, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).
Primary Outcome
Study related adverse events (AEs)
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cisplatin
- PROCEDURE Indocyanine Green (ICG) Image-Guided Surgery
- DRUG Pemetrexed
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-01-10 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 1 |
What NCT03760575 shows while recruiting
NCT03760575 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 32-participant average among 4 other Mesotheliomas Pleural trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Mesotheliomas Pleural appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03760575 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03760575 about?
NCT03760575 is a clinical study titled "Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)". The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).
What is the current status of trial NCT03760575?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-01-10. Estimated completion is 2027-02-01.
What conditions does trial NCT03760575 study?
This clinical trial studies the following conditions: Mesotheliomas Pleural.
What interventions are being tested in trial NCT03760575?
The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Indocyanine Green (ICG) Image-Guided Surgery (PROCEDURE), Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT03760575?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03760575 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesotheliomas Pleural
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI